Pharmaceutical

EMA accepts for review Iveric Bio’s MAA for geographic atrophy therapy

Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.

Aug 18, 2023 - 20:00
EMA accepts for review Iveric Bio’s MAA for geographic atrophy therapy
Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.
Read the original article

Tags:

Previous Article

How competitive intelligence can give pharma companies an edge

Next Article

Nuvectis receives orphan drug designation for cholangiocarcinoma therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.

STAT+: Thermo Fisher just opened a $180 million plant. ...

Sep 22, 2023

STAT+: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac

STAT+: GSK settles first lawsuit set for a U.S. trial o...

Jun 24, 2023

STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research

STAT+: J&J to emphasize cancer drugs and stop much of i...

Dec 5, 2023